Literature DB >> 16912206

The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients.

Nora Sommerfeldt1, Florian Schütz, Christoph Sohn, Joanna Förster, Volker Schirrmacher, Philipp Beckhove.   

Abstract

We analyzed the T-cell repertoires from the bone marrow of 39 primary operated breast cancer patients and 11 healthy female donors for the presence and frequencies of spontaneously induced effector/memory T lymphocytes with peptide-HLA-A2-restricted reactivity against 10 breast tumor-associated antigens (TAA) and 3 normal breast tissue-associated antigens by short-term IFN-gamma enzyme-linked immunospot (ELISpot) analysis. Sixty-seven percent of the patients recognized TAAs with a mean frequency of 144 TAA reactive cells per 10(6) T cells. These patients recognized simultaneously an average of 47% of the tested TAAs. The T-cell repertoire was highly polyvalent and exhibited pronounced interindividual differences in the pattern of TAAs recognized by each patient. Strong differences of reactivity were noticed between TAAs, ranging from 100% recognition of prostate-specific antigen(p141-149) to only 25% recognition of MUC1(p12-20) or Her-2/neu(p369-377). In comparison with TAAs, reactivity to normal breast tissue-associated antigens was lower with respect to the proportions of responding patients (30%) and recognized antigens (27%), with a mean frequency of only 85/10(6) T cells. Healthy individuals also contained TAA-reactive T cells but this repertoire was more restricted and the frequencies were in the same range as T cells reacting to normal breast tissue-associated antigens. Our data show a highly individual T-cell repertoire for recognition of TAAs in breast cancer patients. This has potential relevance for T-cell immune diagnostics, for tumor vaccine design, and for predicting immune responsiveness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912206     DOI: 10.1158/0008-5472.CAN-05-4201

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.

Authors:  Philipp Beckhove; Rolf Warta; Britt Lemke; Diana Stoycheva; Frank Momburg; Martina Schnölzer; Uwe Warnken; Hubertus Schmitz-Winnenthal; Rezvan Ahmadi; Gerhard Dyckhoff; Mariana Bucur; Simone Jünger; Thomas Schueler; Volker Lennerz; Thomas Woelfel; Andreas Unterberg; Christel Herold-Mende
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.

Authors:  Christoph Reissfelder; Slava Stamova; Christina Gossmann; Marion Braun; Andreas Bonertz; Ute Walliczek; Mario Grimm; Nuh N Rahbari; Moritz Koch; Maral Saadati; Axel Benner; Markus W Büchler; Dirk Jäger; Niels Halama; Khashayarsha Khazaie; Jürgen Weitz; Philipp Beckhove
Journal:  J Clin Invest       Date:  2014-12-22       Impact factor: 14.808

3.  Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer.

Authors:  Seyer Safi; Yoshikane Yamauchi; Anchana Rathinasamy; Slava Stamova; Martin Eichhorn; Arne Warth; Geraldine Rauch; Hendrik Dienemann; Hans Hoffmann; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2017-09-08       Impact factor: 8.110

4.  Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.

Authors:  Edith A Perez; Karla V Ballman; Kathy S Tenner; E Aubrey Thompson; Sunil S Badve; Helen Bailey; Frederick L Baehner
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

5.  Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.

Authors:  Friedrich H Schmitz-Winnenthal; Nicolas Hohmann; Andreas G Niethammer; Tobias Friedrich; Heinz Lubenau; Marco Springer; Klaus M Breiner; Gerd Mikus; Jürgen Weitz; Alexis Ulrich; Markus W Buechler; Frank Pianka; Ulla Klaiber; Markus Diener; Christine Leowardi; Simon Schimmack; Leila Sisic; Anne-Valerie Keller; Ruhan Koc; Christoph Springfeld; Philipp Knebel; Thomas Schmidt; Yingzi Ge; Mariana Bucur; Slava Stamova; Lilli Podola; Walter E Haefeli; Lars Grenacher; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2015-03-16       Impact factor: 8.110

6.  Breast Cancer Update 2014 - Focus on the Patient and the Tumour.

Authors:  N Maass; F Schütz; P A Fasching; T Fehm; W Janni; S Kümmel; H-C Kolberg; D Lüftner; M Wallwiener; M P Lux
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-02       Impact factor: 2.915

7.  Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma.

Authors:  Andreas Bonertz; Jürgen Weitz; Dong-Ho Kim Pietsch; Nuh N Rahbari; Christoph Schlude; Yingzi Ge; Simone Juenger; Israel Vlodavsky; Khashayarsha Khazaie; Dirk Jaeger; Christoph Reissfelder; Dalibor Antolovic; Maximilian Aigner; Moritz Koch; Philipp Beckhove
Journal:  J Clin Invest       Date:  2009-10-05       Impact factor: 14.808

8.  A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.

Authors:  Friedrich H Schmitz-Winnenthal; Nicolas Hohmann; Thomas Schmidt; Lilli Podola; Tobias Friedrich; Heinz Lubenau; Marco Springer; Sébastien Wieckowski; Klaus M Breiner; Gerd Mikus; Markus W Büchler; Anne-Valerie Keller; Ruhan Koc; Christoph Springfeld; Phillip Knebel; Mariana Bucur; Lars Grenacher; Walter E Haefeli; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2018-01-16       Impact factor: 8.110

9.  First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.

Authors:  Chrystelle Brignone; Maya Gutierrez; Fawzia Mefti; Etienne Brain; Rosana Jarcau; Frédérique Cvitkovic; Nabil Bousetta; Jacques Medioni; Joseph Gligorov; Caroline Grygar; Manon Marcu; Frédéric Triebel
Journal:  J Transl Med       Date:  2010-07-23       Impact factor: 5.531

10.  High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow.

Authors:  J Joseph Melenhorst; Phillip Scheinberg; Pratip K Chattopadhyay; Emma Gostick; Kristin Ladell; Mario Roederer; Nancy F Hensel; Daniel C Douek; A John Barrett; David A Price
Journal:  Blood       Date:  2008-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.